Insmed Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Great. Good afternoon, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan, and we're continuing the 40th Healthcare Conference this year with Insmed. I'm joined by the company's CEO, Will Lewis, who's going to give a presentation. It's going to be followed by some Q&A. (Operator Instructions)
So let me turn it over to Will.
Thank you, Jessica. Before I begin, please let me draw your attention to our forward-looking statement slide which highlights the uncertainties inherent in making forward-looking statements and also references our public filings, which I encourage you to read for further context. If you can please turn to Slide 4, titled building a leading global biotech company.
If I can leave you with 1 thought at the end of this session, it's this. The company you hear about today is not yesterday's Insmed. The Insmed of just 2 years ago has dramatically evolved and it
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |